Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Cold Agglutinin Disease
NCT05096403Phase 3Completed
- Sponsor
- Sobi
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- PEGylated Peptides
- Countries
- 14
01
Overview
A Phase 3 trial of pegcetacoplan in cold agglutinin disease (CAD), sponsored by Sobi. Started Oct 2022; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT05096403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096403.